Henderson Jane 4

What Happened Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold a total of 2,000 shares in open-market transactions on February 2, 2026, generating approximately $131,629. The sales broke down as: 792 shares at a weighted average of $65.21 ($51,646), 1,108 shares at a weighted average of $66.15 ($73,294), and 100 shares at $66.89 ($6,689). These were dispositions (sales), not purchases.

Key Details

• Transaction date: February 2, 2026 (reported via Form 4 filed Feb 4, 2026).
• Shares sold: 2,000 total (792 @ $65.21; 1,108 @ $66.15; 100 @ $66.89). Total proceeds ≈ $131,629.
• Footnotes: F1—transactions executed pursuant to a Rule 10b5-1 trading plan adopted Sept 2, 2025. F2 & F3—two reported prices are weighted averages; sales occurred across price ranges ($64.80–$65.61 and $65.84–$66.75); breakdowns available on request.
• Shares owned after transaction: not stated in the provided filing excerpt.
• Timeliness: Filing appears timely (Form 4 filed Feb 4 for Feb 2 transactions); no late filing indicated.

Context

• These were open-market sales under a pre-established 10b5-1 plan, which typically reflect prearranged transactions rather than ad hoc insider trades. Sales do not necessarily signal a change in the insider’s view of the company; they may be for diversification, liquidity, or other personal reasons.